within Pharmacolibrary.Drugs.ATC.N;

model N07AA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Distigmine is a carbamate inhibitor of acetylcholinesterase used in the management of myasthenia gravis and occasionally for atonic bladder. Unlike other cholinesterase inhibitors, distigmine has a relatively long duration of action and has previously been marketed in several countries, although its use has become rare due to risk of cholinergic crisis. It is not widely approved or used today.</p><h4>Pharmacokinetics</h4><p>Estimated typical adult pharmacokinetic parameters based on related literature of quaternary ammonium carbamate acetylcholinesterase inhibitors. No direct human PK studies for distigmine with specific parameter reporting found.</p><h4>References</h4><ol><li><p>Vree, TB, Waitzinger, J, Hammermaier, A, &amp; Radhofer-Welte, S (1999). Absolute bioavailability, pharmacokinetics, renal and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine-bromide in healthy volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 37(8) 393–403. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10475142/&quot;>https://pubmed.ncbi.nlm.nih.gov/10475142</a></p></li><li><p>Ito, Y, Harada, T, Fushimi, K, Kagawa, Y, Oka, H, Nakazawa, H, Homma, R, Kato, Y, &amp; Yamada, S (2010). Pharmacokinetic and pharmacodynamic analysis of acetylcholinesterase inhibition by distigmine bromide in rats. <i>Drug metabolism and pharmacokinetics</i> 25(3) 254–261. DOI:<a href=&quot;https://doi.org/10.2133/dmpk.25.254&quot;>10.2133/dmpk.25.254</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20610884/&quot;>https://pubmed.ncbi.nlm.nih.gov/20610884</a></p></li><li><p>Harada, T, Fushimi, K, Kato, A, Ito, Y, Nishijima, S, Sugaya, K, &amp; Yamada, S (2010). Demonstration of muscarinic and nicotinic receptor binding activities of distigmine to treat detrusor underactivity. <i>Biological &amp; pharmaceutical bulletin</i> 33(4) 653–658. DOI:<a href=&quot;https://doi.org/10.1248/bpb.33.653&quot;>10.1248/bpb.33.653</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20410601/&quot;>https://pubmed.ncbi.nlm.nih.gov/20410601</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07AA03;
